a0056u
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of November 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Lynparza granted
FDA Priority Review for OlympiA
30 November 2021 07:00 GMT
Lynparza granted
Priority Review in the US for
BRCA-mutated HER2-negative high-risk early breast
cancer
First medicine targeting BRCA mutations to show clinical
benefit in adjuvant setting
AstraZeneca's supplemental New Drug Application (sNDA)
for Lynparza (olaparib) has been accepted and granted
Priority Review in the US for the adjuvant treatment of patients
with BRCA-mutated (BRCAm) HER2-negative high-risk early breast
cancer who have already been treated with chemotherapy either
before or after surgery.
Lynparza is being jointly
developed and commercialised by AstraZeneca and
MSD.
The Food and Drug Administration (FDA) grants Priority Review to
applications for medicines that offer significant advantages over
available options by demonstrating safety or efficacy improvements,
preventing serious conditions, or enhancing patient
compliance.1 The
Prescription Drug User Fee Act date, the FDA action date for their
regulatory decision, is during the first quarter of
2022.
Breast cancer is now the most diagnosed cancer worldwide with an
estimated 2.3 million patients diagnosed in
2020.2 Nearly
91% of all breast cancer patients are diagnosed at an early stage
of disease and BRCA mutations are found in approximately 5% of
patients.3,4,5
The sNDA was based on results from the OlympiA Phase III
trial presented during
the 2021 American Society of Clinical Oncology Annual Meeting and
simultaneously published in The
New England Journal of Medicine.
These results showed Lynparza demonstrated a statistically significant and
clinically meaningful improvement in invasive disease-free survival
(iDFS), reducing the risk of invasive breast cancer recurrence,
second cancers or death by 42% versus placebo (based on a hazard
ratio of 0.58; 99.5% confidence interval 0.41-0.82; p<0.0001).
The safety and tolerability profile of Lynparza in this trial was in line with that observed
in prior clinical trials.
Lynparza is approved
in the
US, EU, Japan and
several other countries for the treatment of patients with germline
BRCAm, HER2-negative, metastatic breast cancer previously treated
with chemotherapy based on results from the OlympiAD Phase III
trial. In the EU, this indication also includes patients with
locally advanced breast cancer.
Notes
Early breast cancer
Early breast cancer is defined as disease confined to the breast
with or without regional lymph node involvement, and the absence of
distant metastatic disease.6 The
5-year survival rate is 99% for localised breast cancer (only found
in the breast area) and 86% for regional breast cancer (cancer that
has spread outside the breast to nearby structures or lymph
nodes).3 Despite
advancements in the treatment of early breast cancer, up to 30% of
patients with high-risk clinical and/or pathologic features, such
as BRCA mutations, recur within the first few
years.7,8
Breast cancer is one of the most biologically diverse tumour types
with various factors fuelling its development and
progression.9 The
discovery of biomarkers in the development of breast cancer has
greatly impacted scientific understanding of the
disease.10
OlympiA
OlympiA is a Phase III, double-blind, parallel group,
placebo-controlled, multicentre trial testing the efficacy and
safety of Lynparza tablets versus placebo as adjuvant treatment
in patients with germline BRCAm high-risk HER2-negative early
breast cancer, who have completed definitive local treatment and
neoadjuvant or adjuvant chemotherapy.11
The primary endpoint of the trial is iDFS defined as time from
randomisation to date of first loco-regional or distant recurrence
or new cancer or death from any cause.11
The OlympiA Phase III trial is led by the Breast International
Group (BIG) in partnership with the Frontier Science &
Technology Research Foundation (FSTRF), NRG Oncology, AstraZeneca
and MSD.11
BRCA
BRCA1 and BRCA2 are human genes that produce proteins responsible
for repairing damaged DNA and play an important role maintaining
the genetic stability of cells.11
When either of these genes is mutated or altered such that its
protein product either is not made or does not function correctly,
DNA damage may not be repaired properly, and cells become unstable.
As a result, cells are more likely to develop additional genetic
alterations that can lead to cancer and confer sensitivity
to PARP inhibitors including Lynparza.12-15
Lynparza
Lynparza (olaparib) is a
first-in-class PARP inhibitor and the first targeted treatment to
block DNA damage response (DDR) in cells/tumours harbouring a
deficiency in homologous recombination repair (HRR), such as those
with mutations in BRCA1 and/or BRCA2, or those where deficiency is
induced by other agents (such as new hormonal
agents).
Inhibition of PARP with Lynparza leads to the trapping of PARP bound to DNA
single-strand breaks, stalling of replication forks, their collapse
and the generation of DNA double-strand breaks and cancer cell
death. Lynparza is being tested in a range of PARP-dependent
tumour types with defects and dependencies in the DDR
pathway.
Lynparza is currently
approved in a number of countries, including those in the EU, for
the maintenance treatment of platinum-sensitive relapsed ovarian
cancer. It is approved in the US, the EU, Japan, China, and several
other countries as 1st-line maintenance treatment of BRCA-mutated
advanced ovarian cancer following response to platinum-based
chemotherapy.
It is also approved in the US, EU and Japan as a 1st-line
maintenance treatment with bevacizumab for patients with
HRD-positive advanced ovarian cancer (BRCAm and/or genomic
instability).
Lynparza is approved in
the US, Japan, and a number of other countries for germline
BRCA-mutated, HER2-negative, metastatic breast cancer, previously
treated with chemotherapy; in the EU, this includes locally
advanced breast cancer.
It is also approved in the US, the EU, Japan and several other
countries for the treatment of germline BRCAm metastatic pancreatic
cancer.
Lynparza is approved in
the US for HRR gene-mutated metastatic castration-resistant
prostate cancer (BRCAm and other HRR gene mutations) and in the EU
and Japan for BRCAm metastatic castration-resistant prostate
cancer.
Regulatory reviews are underway in several countries for ovarian,
breast, pancreatic and prostate cancers. Lynparza, which is being jointly developed and
commercialised by AstraZeneca and MSD, has been used to treat over
40,000 patients worldwide.
Lynparza has the broadest
and most advanced clinical trial development programme of any PARP
inhibitor, and AstraZeneca and MSD are working together to
understand how it may affect multiple PARP-dependent tumours as a
monotherapy and in combination across multiple cancer
types.
Lynparza is the foundation
of AstraZeneca's industry-leading portfolio of potential new
medicines targeting DDR mechanisms in cancer
cells.
The AstraZeneca and MSD strategic oncology
collaboration
In July 2017, AstraZeneca and Merck & Co., Inc., Kenilworth,
NJ, US (known as MSD outside the US and Canada) announced a global
strategic oncology collaboration to co-develop and
co-commercialise Lynparza,
the world's first PARP inhibitor, and Koselugo (selumetinib),
a mitogen-activated protein kinase (MEK) inhibitor, for multiple
cancer types.
Working together, the companies will
develop Lynparza and Koselugo in
combination with other potential new medicines and as
monotherapies. Independently, the companies will
develop Lynparza and Koselugo in
combination with their respective PD-L1 and PD-1
medicines.
AstraZeneca in breast cancer
Driven by a growing understanding of breast cancer biology,
AstraZeneca is starting to challenge, and redefine, the current
clinical paradigm for how breast cancer is classified and treated
to deliver even more effective treatments to patients in need -
with the bold ambition to one day eliminate breast cancer as a
cause of death.
AstraZeneca has a comprehensive portfolio of approved and promising
compounds in development that leverage different mechanisms of
action to address the biologically diverse breast cancer tumour
environment.
AstraZeneca aims to continue to transform outcomes for HR-positive
breast cancer with foundational medicines Faslodex (fulvestrant) and Zoladex (goserelin) and the next-generation
selective estrogen receptor degraders (SERD) and potential new
medicine camizestrant (formerly known as
AZD9833).
Lynparza is a targeted
treatment option for metastatic breast cancer patients with an
inherited BRCA mutation. AstraZeneca with MSD continue to
research Lynparza in early and metastatic breast cancer
patients with a BRCA mutation.
Building on the first approval of Enhertu (trastuzumab deruxtecan), a HER2-directed
antibody-drug conjugate (ADC), in previously treated HER2-positive
metastatic breast cancer, AstraZeneca and Daiichi Sankyo are
exploring its potential in earlier lines of treatment and in new
breast cancer settings. Results from the DESTINY-Breast03 Phase III
trial showed that Enhertu significantly improved progression-free
survival in patients with HER2-positive metastatic breast
cancer.
To bring much needed treatment options to patients with
triple-negative breast cancer, an aggressive form of breast cancer,
AstraZeneca is testing immunotherapy Imfinzi (durvalumab) in combination with other
oncology medicines, including Lynparza and Enhertu, assessing the potential of AKT kinase inhibitor,
capivasertib, in combination with chemotherapy, and collaborating
with Daiichi Sankyo to explore the potential of TROP2-directed ADC,
datopotamab deruxtecan.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition
to provide cures for cancer in every form, following the science to
understand cancer and all its complexities to discover, develop and
deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It
is through persistent innovation that AstraZeneca has built one of
the most diverse portfolios and pipelines in the industry, with the
potential to catalyse changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1. US Food and Drug Administration. Priority Review. Available
at: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review.
Accessed November 2021.
2. GLOBOCAN. Breast Cancer. Available at https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. Accessed
November 2021.
3. Cancer.org. Survival rates for breast cancer. Available
at https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html.
Accessed November 2021.
4. De Talhouet S, et al. Clinical outcome of
breast cancer in carriers of BRCA1 and BRCA2 mutations according to
molecular subtypes.
Scientific Reports.
2020;10:7073.
5. Cancer.gov. Early-stage breast cancer. Available
at https://www.cancer.gov/publications/dictionaries/cancer-terms/def/early-stage-breast-cancer.
Accessed November 2021.
6. WHO. Early stage breast cancer. Available
at https://www.who.int/selection_medicines/committees/expert/20/applications/EarlyStageBreast.pdf?ua=1.
Accessed November 2021.
7. Johnston S, et al. Abemaciclib Combined With Endocrine Therapy
for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk,
Early Breast Cancer (monarchE). J Clin
Oncol. 2020;38(34):3987-3998.
8. Smith KL, Isaacs C. BRCA mutation testing in determining
breast cancer therapy. Cancer J. 2011;17(6):492-499.
doi:10.1097/PPO.0b013e318238f579
9. Yersal O, and Barutca S. Biological Subtypes of Breast Cancer:
Prognostic and therapeutic implications. World J Clin
Oncol.
2014;5(3):412-424.
10. Rivenbark A, et al. Molecular and Cellular Heterogeneity in Breast
Cancer: Challenges for Personalized
Medicine. Am J Pathol. 2013;183(4):1113-1124.
11. ClinicalTrials.gov. Olaparib as Adjuvant Treatment in Patients
with Germline BRCA Mutated High Risk HER2 Negative Primary Breast
Cancer (OlympiA). Available at https://clinicaltrials.gov/ct2/show/NCT02032823.
Accessed November 2021.
12. Roy R, et al. BRCA1 and BRCA2: Different Roles in a Common
Pathway of Genome Protection. Nat Rev
Cancer.
12(1):68-78.
13. Wu J, et al. The Role of BRCA1 in DNA Damage
Response. Protein
Cell.
2010;1(2):117-123.
14. Gorodetska I, et al. BRCA Genes: The Role in Genome Stability, Cancer
Stemness and Therapy Resistance. J Cancer. 2019;10(9):2109-2127.
15. Li H, et al. PARP Inhibitor Resistance: The Underlying
Mechanisms and Clinical Implications. Mol Cancer. 2020;19:107.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
30 November 2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|